Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03584009
Title A Phase II Study Comparing The Efficacy Of Venetoclax + Fulvestrant Vs. Fulvestrant In Women With Estrogen Receptor-Positive, Her2-Negative Locally Advanced Or Metastatic Breast Cancer Who Experienced Disease Recurrence Or Progression During Or After CDK4/6 Inhibitor Therapy
Recruitment Terminated
Gender female
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche

estrogen-receptor positive breast cancer



Fulvestrant + Venetoclax

Age Groups: senior | adult
Covered Countries USA | DEU | CAN

No variant requirements are available.